Companies Investors People

Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

Contact
Request a Demo
Request Data Updates
Add a Company

Research

Companies
Investors
People

aVenture

Download App
Pricing

Resources

Documentation
Use Cases
CLI
MCP
Feature Requests
Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading

Restor Metabolix - aVenture Company Research

Restor Metabolix

Restor Metabolix

Restor Metabolix, a Georgia-based firm, offers scientifically proven diabetic treatments and metabolic disorder solutions, focusing on insulin desensitization.

Marietta, GA, US🇺🇸

Founded

Restor Metabolix, based in Marietta, Georgia, is dedicated to providing scientifically proven treatments for diabetes and metabolic disorders. The company specializes in physiologic insulin desensitization, a method that uses insulin to bio-mimic normal physiology and reduce insulin resistance, thereby aiding blood sugar conversion into energy. Restor Metabolix equips and trains physicians on this multi-patented, physician-directed treatment modality, aiming to reverse the underlying causes of most diabetic symptoms.

Nicholas Reiter, with over a decade of experience in creating and implementing organizational systems and training modules, is a notable figure associated with Restor Metabolix. The company has achieved significant milestones in the medical field by offering innovative solutions that address the root causes of diabetes. Their impact is evident in the improved health outcomes for patients undergoing their treatment regimen, positioning Restor Metabolix as a leader in metabolic disorder therapies.

Restor Metabolix - Similar Companies

Metabolic Solutions Development

msdrx.com

Satiogen Pharmaceuticals

Endogenex

endogenex.com

Restor Metabolix - Quick Facts

Who are Restor Metabolix's competitors?

Companies similar to Restor Metabolix include Metabolic Solutions Development, Satiogen Pharmaceuticals, Endogenex and Sensulin.

When was Restor Metabolix founded?

Restor Metabolix was founded in 2021.

Where is Restor Metabolix's headquarters located?

Restor Metabolix's headquarters is located in Marietta, GA, US.

When was Restor Metabolix's last funding round?

Restor Metabolix's most recent funding round was for $1M (USD) in October 2022.

How much disclosed funding has Restor Metabolix raised?

Restor Metabolix - Classification

Industry: Professional Service Companies
Ownership: Private
Technology: Telemedicine

As of Oct 26, 2022, Restor Metabolix has disclosed funding of $1M (USD). Undisclosed round amounts are excluded.

How many employees does Restor Metabolix have?

Restor Metabolix has 17 employees as of Feb 5, 2024.

Geographic Exposure

United States

Customer: Enterprise
Main Product: Diabetic Treatments
Metabolic Treatments

Tags: Consulting
Healthtech

NAICS: 620000Health Care and Social Assistance
SIC: 8000Health Services
8040Offices And Clinics Of Other Health Practitioners
8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified

Show 1 more industry code

NAICS: 623000Nursing and Residential Care Facilities

Sensulin

sensulin.com

Exsulin

Microbiome Therapeutics

Glycostasis

Journeys Metabolic

LifestyleRx

lifestylerx.io

Glyscend

glyscend.com

MetaModix

Energesis Pharmaceuticals

Metabolon

metabolon.com

Geminii Health

geminiihealth.com

KinDex Pharmaceuticals